Q-omics provides the consensus-scored CLDN6 profile across patient tissues and cancer cell-line models. CLDN6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CLDN6 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, CLDN6 RNA expression shows 13,641 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where CLDN6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLDN6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLDN6 survival associations across molecular data types. CLDN6 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLDN6 RNA expression–survival associations across cancer types. High CLDN6 expression shows unfavorable associations in KIRC, MESO, BLCA, KIRP, STAD and UCEC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CLDN6 RNA expression.
This table summarizes CLDN6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CLDN6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLDN6 shows lower tumor expression in KIRC and KICH and higher tumor expression in LUAD, STAD, HNSC and BRCA. The KIRC box plot shows higher CLDN6 RNA expression in normal versus tumor tissue (log2 FC = −0.517, t-test p < 0.001).
This table shows molecular features associated with CLDN6 in patient tissues and cancer cell lines. In patient samples, CLDN6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CLDN6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and OVARY.
